Acute coronary syndromes in cancer patients.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
11
6
2020
medline:
20
5
2021
entrez:
11
6
2020
Statut:
ppublish
Résumé
: Cardiovascular disease and cancer are responsible for the majority of deaths in the Western world. These two entities share common risk factors and their intersection will be more and more frequent in future due to general population aging and long-term cancer control. Clinical presentation, management and outcome of acute coronary syndromes (ACS) in cancer patients could differ from noncancer ones. Cancer patients were frequently excluded from clinical trials and so the paucity of data further complicates the scenario. The management of ACS in cancer patients represents a unique setting in which the risk/benefit ratio of invasive treatment should be carefully evaluated. This review focused on the available evidence of all aspects of ACS in cancer patients providing a guide to a multidisciplinary approach.
Identifiants
pubmed: 32520859
doi: 10.2459/JCM.0000000000000993
pii: 01244665-202012000-00003
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-952Références
Yusuf SW, Cipolla C, Durand JB, Lenihan DJ. Cancer and cardiovascular disease. Cardiol Res Pract 2011; 2011:943748.
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133:1104–1114.
Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99:206–214.
Banasiak W, Zymlinski R, Undas A. Optimal management of cancer patients with acute coronary syndrome. Pol Arch Intern Med 2018; 128:244–253.
Nohria A, Groarke JD. Management of acute coronary syndromes in patients with cancer: room for improvement. Eur Heart J 2019; 40:1801–1803.
Ganatra S, Sharma A, Levy MS. A differing opinion on primary percutaneous coronary intervention in patients who have had cancer: stent choice in onco-cardiology revisited. Mayo Clin Proc 2017; 92:1315–1316.
Cordero A, López-Palop R, Carrillo P, et al. Prevalence and postdischarge incidence of malignancies in patients with acute coronary syndrome. Rev Esp Cardiol 2018; 71:267–273.
Park JY, Guo W, Al-Hijji M, et al. Acute coronary syndromes in patients with active hematologic malignancies – incidence, management, and outcomes. Int J Cardiol 2019; 275:6–12.
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70:926–938.
Al-Hawwas M, Tsitlakidou D, Gupta N, Iliescu C, Cilingiroglu M, Marmagkiolis K. Acute coronary syndrome management in cancer patients. Curr Oncol Rep 2018; 20:78.
Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486–1493.
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109:1878–1886.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987–998.
Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366:2087–2106.
Cheng YJ, Nie XY, Ji CC, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc 2017; 6:pii e005633.
Van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 2017; 35:1171–1178.
Marmagkiolis K, Finch W, Tsitlakidou D, et al. Radiation toxicity to the cardiovascular system. Curr Oncol Rep 2016; 18:15.
Lind PA, Pagnanelli R, Marks LB, et al. Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys 2003; 55:914–920.
Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018; 10:1758835918780140.
Jensen SA, Sorensen JB. 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012; 69:57–64.
Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29:3466–3473.
Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231–2247.
Hanchate LP, Sharma SR, Madyalkar S. Cisplatin induced acute myocardial infarction and dyslipidemia. J Clin Diagn Res 2017; 11:OD05–OD07.
Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety. Int J Cardiol 2013; 168:2453–2461.
Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma 2017; 58:1455–1467.
Pouwer MG, Pieterman EJ, Verschuren L, et al. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med 2018; 5:55.
Oren O, Herrmann J. Arterial events in cancer patients-the case of acute coronary thrombosis. J Thorac Dis 2018; 10: (Suppl 35): S4367–S4385.
Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol 2013; 62:1748–1758.
Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013; 24:393–400.
Goubran HA, Stakiw J, Radosevic M, et al. Platelet-cancer interactions. Semin Thromb Hemost 2014; 40:296–305.
Huong PT, Nguyen LT, Nguyen XB, Lee SK, Bach DH. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel) 2019; 11:pii E240.
Tuzovic M, Herrmann J, Iliescu C, Marmagkiolis K, Ziaeian B, Yang EH. Arterial thrombosis in patients with cancer. Curr Treat Options Cardiovasc Med 2018; 20:40.
Bauer AT, Suckau J, Frank K, et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood 2015; 125:3153–3163.
Yang AJ, Wang M, Wang Y, et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis 2018; 7:12.
Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 2017; 16:5–12.
Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné JM. BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis? TH Open 2018; 2:e68–e88.
Li W, Garcia D, Cornell RF, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncol 2017; 3:980–988.
Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108:403.
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142–152.
Thygesen K, Alpert JS, Jaffe AS, et al. Executive group on behalf of the joint european society of cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) task force for the universal definition of myocardial infarction fourth universal definition of myocardial infarction (2018). Glob Heart 2018; 13:305–338.
Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B. TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart 2015; 101:101–106.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012; 35:443–450.
Munoz E, Iliescu G, Vejpongsa P, et al. Takotsubo stress cardiomyopathy: ‘Good News’ in cancer patients? J Am Coll Cardiol 2016; 68:1143–1144.
Kobayashi N, Hata N, Yokoyama S, Shinada T, Shirakabe A, Mizuno K. A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nippon Med Sci 2009; 76:27–33.
Lee S, Lim SP, Yu JH, et al. Stress-induced cardiomyopathy during pulmonary resection (Takotsubo syndrome) – a case report. Korean J Thorac Cardiovasc Surg 2011; 44:294–297.
Smith SA, Auseon AJ. Chemotherapy-induced Takotsubo cardiomyopathy. Heart Fail Clin 2013; 9:233–242.
Giza DE, Kostas M, Elie M, et al. Management of CAD in patients with active cancer: the interventional cardiologists’ perspective. Curr Cardiol Rep 2017; 19:56.
Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol 2016; 142:471–479.
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37:267–315.
Cheung WY, Levin R, Setoguchi S. Appropriateness of cardiovascular care in elderly adult cancer survivors. Med Oncol 2013; 30:561.
Handa N, McGregor CG, Danielson GK, et al. Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. J Thorac Cardiovasc Surg 1999; 117:1136–1142.
Liang JJ, Sio TT, Slusser JP, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv 2014; 7:1412–1420.
Balanescu DV, Donisan T, Dayah T, et al. Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. Int J Cardiovasc Imaging 2019; 35:759–760.
Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 2016; 87:E202–E223.
Iliescu CA, Cilingiroglu M, Giza DE, et al. Bringing on the light’ in a complex clinical scenario: optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J 2017; 194:83–91.
Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv 2017; 10:2334–2337.
Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A prespecified analysis from the ZEUS trial. JACC Cardiovasc Interv 2016; 9:426–436.
Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 373:2038–2047.
Garot P, Morice MC, Tresukosol D, et al. 2-Year outcomes of high bleeding risk patients after polymer-free drug-coated stents. J Am Coll Cardiol 2017; 69:162–171.
Inohara T, Endo A, Melloni C. Unmet needs in managing myocardial infarction in patients with malignancy. Front Cardiovasc Med 2019; 6:57.
Lestuzzi C, Vaccher E, Talamini R, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol 2014; 25:1059–1064.
Minson AG, Cummins K, Fox L, et al. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Blood Adv 2019; 3:1084–1091.
Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58:487–493.
Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8:191–202.
Lestuzzi C, Crivellari D, Rigo F, Viel E, Meneguzzo N. Capecitabine cardiac toxicity presenting as effort angina: a case report. J Cardiovasc Med (Hagerstown) 2010; 11:700–703.
Sorrentino MF, Truesdell AG. 5-Fluorouracil-induced coronary thrombosis: a case report and review of the literature. J Cardiol Cases 2012; 6:e20–e22.
Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355:1075–1076.
Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112:1949–1953.
van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 3:467–475.
Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30:3752–3763.
Lubberts S, Boer H, Altena R, et al. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer 2016; 63:180–188.
Grilz E, Königsbrügge O, Posch F, et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica 2018; 103:1549–1556.
Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia 2017; 31:2388–2397.
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 2016; 17:611–625.
Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Kihara Y. Comparison of treatment and outcome of acute myocardial infarction between cancer patients and noncancer patients. Int J Cardiol 2013; 167:2335–2337.
Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J 2010; 37:336–340.
Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D. Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care 2018; 7:639–645.
Pothineni NV, Shah NN, Rochlani Y, et al. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med 2017; 5:482.
Reed GW, Masri A, Griffin BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv 2016; 9:pii e003483.
Landes U, Kornowski R, Bental T, et al. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis 2017; 28:5–10.
Iannaccone M, D’Ascenzo F, Vadalà P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018; 7:631–638.
Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart 2018; 104:1647–1653.
Velders MA, Boden H, Hofman SH, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 2013; 112:1867–1872.
Hess CN, Roe MT, Clare RM, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary. J Am Heart Assoc 2015; 4:pii e001779.
Wang F, Gulati R, Lennon RJ, et al. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc 2016; 91:1680–1692.
Jacobs JA, Pickworth K, Boudoulas KD, Hinkley M, McLaughlin E, Blais D. Outcomes for cancer patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Revasc Med 2019; 20:711–715.
Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019; 40:1790–1800.
Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J 2017; 187:98–103.
Schömig K, Ndrepepa G, Mehilli J, Pache J, Kastrati A, Schömig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv 2007; 70:359–365.
Abbott JD, Ahmed HN, Vlachos HA, Selzer F, Williams DO. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 100:190–195.
Tabata N, Sueta D, Yamamoto E, et al. KUMA study investigators. Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 2018; 4:290–300.